TCW Group Inc. Purchases Shares of 22,865 Edwards Lifesciences Co. (NYSE:EW)

TCW Group Inc. purchased a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 22,865 shares of the medical research company’s stock, valued at approximately $1,693,000.

Other hedge funds have also modified their holdings of the company. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Edwards Lifesciences in the 4th quarter valued at approximately $30,000. FSA Wealth Management LLC purchased a new position in shares of Edwards Lifesciences in the 3rd quarter valued at approximately $30,000. Prospera Private Wealth LLC purchased a new position in shares of Edwards Lifesciences in the 3rd quarter valued at approximately $32,000. Avior Wealth Management LLC raised its position in shares of Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares during the last quarter. Finally, Roble Belko & Company Inc purchased a new position in shares of Edwards Lifesciences in the 4th quarter valued at approximately $46,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the transaction, the chief financial officer now owns 30,561 shares in the company, valued at $2,315,301.36. The trade was a 26.91 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the transaction, the vice president now owns 23,189 shares in the company, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 26,489 shares of company stock worth $2,002,829. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $72.72 on Tuesday. The company’s fifty day moving average price is $72.83 and its 200 day moving average price is $70.13. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The stock has a market capitalization of $42.89 billion, a P/E ratio of 10.43, a P/E/G ratio of 4.82 and a beta of 1.11. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Morgan Stanley increased their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 12th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their price target for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Canaccord Genuity Group increased their price target on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a report on Thursday, February 13th. The Goldman Sachs Group increased their price target on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. Finally, Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.